Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

Hemispherx Biopharma to Present at the 9th Annual LD Micro Main Event

GlobeNewswire November 21, 2016

Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended September 30, 2016

GlobeNewswire November 14, 2016

Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15, 2016

GlobeNewswire November 10, 2016

Hemispherx Biopharma Featured in Corporate America News Magazine Special Report “Capturing the Power of Immune Response to Treat Disease: Biotech Bounce Back”

GlobeNewswire November 8, 2016

Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/ME

GlobeNewswire October 31, 2016

Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone

GlobeNewswire October 19, 2016

Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case

GlobeNewswire September 22, 2016

Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards

GlobeNewswire September 19, 2016

Hemispherx Biopharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire September 6, 2016

12 Biggest Mid-Day Losers For Wednesday

Benzinga.com  August 31, 2016

Hemispherx Biopharma, Inc. Announces $5 Million Registered Direct Offering

GlobeNewswire August 31, 2016

Hemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA

GlobeNewswire August 29, 2016

Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma

PR Newswire August 29, 2016

Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic

GlobeNewswire August 24, 2016

Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic

GlobeNewswire August 23, 2016

Hemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and Pharmaceutical Expertise

GlobeNewswire August 19, 2016

Hemispherx Biopharma Announces 1-for-12 Reverse Stock Split

GlobeNewswire August 17, 2016

Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2016

GlobeNewswire August 15, 2016

Hemispherx Biopharma Conducts an Interview with The Wall Street Transcript

GlobeNewswire August 15, 2016

Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen®

GlobeNewswire July 27, 2016